Skip to main content
. 2022 Sep 5;65:101590. doi: 10.1016/j.molmet.2022.101590

Figure 6.

Figure 6

GLP-1R activation in the nodose ganglia lowers postprandial plasma TG and TRL and is necessary for the anti-lipemic effects of portal GLP-1.A-D: Chow-fed Syrian golden hamsters were fasted for 16 h then received a bilateral nodose ganglion injection of Exendin-4 (250 ng in 1 μl PBS), Exendin 9-39 (500 ng in 1 μl PBS), Exendin 9-39 followed 10 min later by Exendin-4, or vehicle control (1 μl PBS). E-L: Chow-fed Syrian golden hamsters were fasted for 16 h then received bilateral nodose ganglion injections of either Exendin 9-39 (500 ng in 1 μl PBS; PVI-(XX) + NG-(9–39)) or vehicle (1 μl PBS; PVI-(XX) + NG-(Veh). Following this, hamsters received a portal vein injection of either GLP-1(7-36) (10 μg/kg; PVI-(GLP-1) + NG-(XX)) or vehicle (PBS; PVI-(Veh) + NG-(XX)). Following treatment all hamsters were fat loaded with an oral gavage of olive oil (200 μl) and received an IP injection of Pluronic F-127 (2  g/kg). Blood was drawn over a 6 h period via retro-orbital bleed. (A/E) Plasma TG, (B/F) plasma TG AUC, (C/I) TRL TG, (D/J) TRL TG AUC, (G) plasma cholesterol, (H) plasma cholesterol AUC, (K) TRL cholesterol, (L) TRL cholesterol AUC. Data is presented as means ± SEM (A-D: n=4–7/group; E-L: n=5/group). (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). A–D: ∗; Vehicle vs. Exendin-4, ˆ; Exendin 9-39 vs. Exendin 4, @; Exendin 9-39 + Exendin-4 vs. Exendin-4. E–L: ∗; PVI-(Veh) + NG-(Veh) vs. PVI-(GLP-1) + NG-(Veh), ˆ; PVI-(GLP-1) + NG-(9–39) vs. PVI-(GLP-1) + NG-(Veh), $; PVI-(Veh) + NG-(9–39) vs. PVI-(GLP-1) + NG-(Veh).